Beneficial Effects of FPR Agonists on an Animal Model of Early Stage Heart Failure with Preserved Ejection Fraction
FPR 激动剂对射血分数保留的早期心力衰竭动物模型的有益作用
基本信息
- 批准号:10580246
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-10-01 至 2027-03-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdverse eventAgeAge YearsAgonistAnimal ModelAnimalsAreaAttenuatedBloodCardiacCardiac OutputCellsClipCollagenComplexDataDepositionDevelopmentDiffuseDiseaseEFRACEndocardiumExhibitsExposure toFemaleFibroblastsFibrosisFructoseFunctional disorderFutureGoalsHealthHeartHeart DiseasesHeart failureHospitalizationHypertensionInflammationInflammatoryInjury to KidneyKidneyKidney DiseasesLeadLeftLeft Ventricular RemodelingLeft ventricular structureLeucocytic infiltrateLipoxinsMacrophageMediatorMedicareModelingMusMyocardialMyocardial InfarctionMyocardiumNon-Insulin-Dependent Diabetes MellitusObesityOral AdministrationOvariectomyPathway interactionsPatientsPhase I Clinical TrialsPhenotypePhysiologicalPlayPopulationPost-Traumatic Stress DisordersPostmenopauseProcessPropertyRattusRelaxationReportingResearchResearch PriorityResolutionRisk FactorsRodent ModelRoleSeveritiesSteroidsStressTestingTherapeuticTissuesVentricularVeteransWeight GainWomanWorkagedblood pumpcoronary fibrosiscytokinedrinking waterexperiencefMet-Leu-Phe receptorimprovedimproved outcomeinsightinterestmalemenmilitary veterannew therapeutic targetnovelnovel therapeutic interventionpharmacologicpolarized cellpre-clinicalpreservationpreventreceptorstatisticssystemic inflammatory responsetool
项目摘要
Heart failure (HF) is the most common cause of Medicare hospitalizations. About 50% of HF patients suffer from
HF with low ejection fraction (HFrEF) for which there are treatments. The other 50% suffer from HFpEF,
(preserved ejection fraction) characterized by the inability of the left ventricle (LV) to accommodate larger filling
volumes upon greater demands in cardiac output. Currently, no treatments are available for HFpEF and studies
demonstrate a female predominance (2:1 vs. men). Noteworthy, the VA has identified as a research priority
Women Veteran’s health. HFpEF pathophysiology is complex and the cause for female predominance is unclear.
However, studies strongly suggest a role for LV fibrosis in the development of HFpEF which, appears
accentuated in post-menopausal women. Thus, there is a need to identify, evaluate and develop novel
treatments in pre- or later stage HFpEF female animal models targeting fibrosis leading to improved LV function.
Cardiac fibrosis is preceded and orchestrated by dysregulated inflammation where macrophages are key.
Systemic inflammation derived from the presence of kidney disease, obesity, type 2 diabetes and/or
hypertension leading to the activation of pro-inflammatory cytokines was identified as a likely key contributor to
HFpEF. Pharmacologic approaches that non-specifically inhibit inflammation so as to attenuate fibrosis, are
poorly tolerated. However, selective and targeted modulation of inflammation has emerged as a concept
whereby the dysregulated process may be physiologically controlled leading to reduced fibrosis. The discovery
of pro-resolution mediators such as lipoxins and resolvins as well as the identification of their receptors such as
the formyl peptide receptor (FPR), has led to new insights towards addressing unresolved inflammation.
Macrophages express FPR that when stimulated, induce their M2 like polarization to a pro-resolution phenotype.
We utilized FPR agonists in rodent models of myocardial infarction where treatment significantly improves LV
function and reduces non-infarcted area fibrosis. However, no studies have assessed their potential use in pre-
clinical female models of HFpEF. We propose that: “Treatment with FPR agonists polarizes macrophages to a
pro-resolution phenotype limiting adverse left ventricular remodeling and fibrosis in animal models mimicking
HFpEF in women, leading to improved chamber function”. Aim 1 will test if the oral administration of an FPR
agonist (compound 43) to a female animal model of early stage HFpEF prevents the development of fibrosis
leading to the preservation of optimal myocardial material properties and thus, improved left ventricular diastolic
and systolic function. Aim 2 if the oral administration of an FPR agonist to a female animal model of HFpEF
compounded by renal injury ameliorates tissue fibrosis leading to the preservation of optimal myocardial material
properties and thus, improved left ventricular diastolic and systolic function. Aim 3 if the oral administration of an
FPR agonist to female animal models of early stage or compounded HFpEF normalizes blood levels of pro-
inflammatory cytokines and triggers the polarization of macrophages to a pro-resolution phenotype. We will also
perform a broader characterization of the infiltrating leucocyte population as well as macrophage derived
conditioned media treatment of culture cardiac fibroblasts to assess its effects on cell phenotype.
心力衰竭 (HF) 是 Medicare 住院的最常见原因。大约 50% 的心力衰竭患者患有
低射血分数心衰 (HFrEF) 有治疗方法。另外 50% 患有 HFpEF,
(射血分数保留)的特点是左心室 (LV) 无法容纳更大的充盈
体积对心输出量的更大需求。目前,尚无针对 HFpEF 的治疗方法和研究
表现出女性优势(2:1 与男性)。值得注意的是,VA 已将其确定为研究重点
女退伍军人的健康。 HFpEF 病理生理学很复杂,女性占主导地位的原因尚不清楚。
然而,研究强烈表明左心室纤维化在 HFpEF 的发展中发挥着作用,这似乎
在绝经后妇女中尤为突出。因此,需要识别、评估和开发新颖的
在 HFpEF 雌性动物模型前期或后期进行针对纤维化的治疗,从而改善左心室功能。
心脏纤维化是由炎症失调引起的,其中巨噬细胞是关键。
因肾脏疾病、肥胖、2 型糖尿病和/或
导致促炎细胞因子激活的高血压被认为是可能的关键因素
HFpEF。非特异性抑制炎症以减轻纤维化的药理学方法是
耐受性差。然而,选择性和有针对性的炎症调节已成为一个概念
由此,失调的过程可以在生理上得到控制,从而减少纤维化。发现
促分解介质(如脂氧素和分解素)及其受体的鉴定,如
甲酰肽受体(FPR)为解决未解决的炎症带来了新的见解。
巨噬细胞表达 FPR,当受到刺激时,会诱导其 M2 样极化,形成亲分辨率表型。
我们在啮齿动物心肌梗塞模型中使用 FPR 激动剂,治疗可显着改善左心室 (LV)
功能并减少非梗塞区域纤维化。然而,没有研究评估它们在预治疗中的潜在用途。
HFpEF 的临床女性模型。我们建议:“FPR 激动剂治疗使巨噬细胞极化为
模拟动物模型中促消退表型限制不良左心室重塑和纤维化
女性中的 HFpEF,从而改善心室功能”。目标 1 将测试口服 FPR 是否有效
早期 HFpEF 雌性动物模型中的激动剂(化合物 43)可预防纤维化的发展
导致保留最佳的心肌材料特性,从而改善左心室舒张压
和收缩功能。目标 2:向 HFpEF 雌性动物模型口服 FPR 激动剂
加上肾损伤可改善组织纤维化,从而保存最佳的心肌材料
特性,从而改善左心室舒张和收缩功能。目标 3 如果口服
FPR 激动剂对早期雌性动物模型或复合 HFpEF 可使血中亲-
炎症细胞因子并触发巨噬细胞极化为促消退表型。我们还将
对浸润白细胞群以及巨噬细胞衍生的细胞进行更广泛的表征
对培养的心脏成纤维细胞进行条件培养基处理,以评估其对细胞表型的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Francisco J Villarreal其他文献
Francisco J Villarreal的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Francisco J Villarreal', 18)}}的其他基金
Excess O-GlcNAc modification of proteins and myocardial fibrosis
蛋白质的过量 O-GlcNAc 修饰与心肌纤维化
- 批准号:
10265339 - 财政年份:2018
- 资助金额:
-- - 项目类别:
Targeting cellular bioenergetics for the prevention and treatment of diabetes
针对细胞生物能量学预防和治疗糖尿病
- 批准号:
8150760 - 财政年份:2011
- 资助金额:
-- - 项目类别:
Effects of Cocoa Flavonols on Myocardial Infarction Size and Post-Injury Injury
可可黄酮醇对心肌梗死面积和损伤后损伤的影响
- 批准号:
7921723 - 财政年份:2008
- 资助金额:
-- - 项目类别:
Effects of Cocoa Flavonols on Myocardial Infarction Size and Post-Injury Injury
可可黄酮醇对心肌梗死面积和损伤后损伤的影响
- 批准号:
7534759 - 财政年份:2008
- 资助金额:
-- - 项目类别:
Effects of Cocoa Flavonols on Myocardial Infarction Size and Post-Injury Injury
可可黄酮醇对心肌梗死面积和损伤后损伤的影响
- 批准号:
7694384 - 财政年份:2008
- 资助金额:
-- - 项目类别:
26th Annual Meeting of the North Am. Section of the ISHR
第26届北美年会。
- 批准号:
6837277 - 财政年份:2004
- 资助金额:
-- - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
-- - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
-- - 项目类别: